Form 4: Acrivon Therapeutics CFO Adam D. Levy Reports Stock Option Grant

Adam D. Levy, CFO of Acrivon Therapeutics, reports the acquisition of stock options.

Summary

• Adam D. Levy, the Chief Financial Officer of Acrivon Therapeutics, Inc., filed a Form 4 on April 3, 2025, reporting a transaction.
• On April 1, 2025, Levy acquired stock options for 35,209 shares of Acrivon Therapeutics common stock at an exercise price of $1.68 per share.
• These options vest over time, with 25% vesting on April 1, 2026, and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the executive's continued contribution to the company.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.

Risks

• The vesting schedule is contingent upon the Reporting Person's continuous service, so if the Reporting Person leaves the company, they may forfeit unvested options.

Future Outlook

The document does not contain specific forward-looking statements about the company's performance, but the stock option grant suggests an expectation of continued service and contribution from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the CFO's performance leads to company growth.

Key Dates

Keywords

stock options, Form 4, Acrivon Therapeutics, CFO, Adam D. Levy, equity, vesting